Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.970
-0.280 (-6.59%)
At close: Oct 10, 2025, 4:00 PM EDT
4.040
+0.070 (1.76%)
After-hours: Oct 10, 2025, 7:31 PM EDT
Agenus Revenue
Agenus had revenue of $25.69M in the quarter ending June 30, 2025, with 9.28% growth. This brings the company's revenue in the last twelve months to $101.16M, down -19.53% year-over-year. In the year 2024, Agenus had annual revenue of $103.46M, down -33.81%.
Revenue (ttm)
$101.16M
Revenue Growth
-19.53%
P/S Ratio
0.95
Revenue / Employee
$321,854
Employees
316
Market Cap
126.50M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
Dec 31, 2018 | 36.78M | -6.09M | -14.21% |
Dec 31, 2017 | 42.88M | 20.30M | 89.95% |
Dec 31, 2016 | 22.57M | -2.24M | -9.04% |
Dec 31, 2015 | 24.82M | 17.84M | 255.67% |
Dec 31, 2014 | 6.98M | 3.93M | 129.13% |
Dec 31, 2013 | 3.05M | -12.92M | -80.92% |
Dec 31, 2012 | 15.96M | 13.20M | 479.17% |
Dec 31, 2011 | 2.76M | -603.84K | -17.97% |
Dec 31, 2010 | 3.36M | 25.17K | 0.75% |
Dec 31, 2009 | 3.33M | 683.36K | 25.78% |
Dec 31, 2008 | 2.65M | -2.90M | -52.25% |
Dec 31, 2007 | 5.55M | 4.86M | 702.20% |
Dec 31, 2006 | 692.14K | 62.16K | 9.87% |
Dec 31, 2005 | 629.98K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AGEN News
- 4 weeks ago - France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer - Business Wire
- 5 weeks ago - Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 6 weeks ago - Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript) - Seeking Alpha
- 6 weeks ago - Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight - Business Wire
- 7 weeks ago - Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025 - Business Wire
- 2 months ago - Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress - Business Wire
- 2 months ago - Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report - Business Wire
- 2 months ago - Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 - Business Wire